about the author

Max Gelman

Senior Editor

max@endpointsnews.com @MaxGelman
Max Gelman on LinkedIn

Max Gelman writes about the big-picture ideas and trends that drive the biopharma world, with particular interests in immunology and neuroscience. A graduate of Northwestern University, Max joined Endpoints in July 2020 after a few stints covering baseball and college sports. He currently lives in New York City.

author articles

Lat­est sal­vo in Pfiz­er ac­tivist fight; John Car­rol­l's Q3 biotech roundup; In­tel­lia un­veils CRISPR re­sults; and more

5 weeks ago
Weekly

Bris­tol My­ers, Ideaya tout da­ta in sol­id tu­mors with cer­tain ge­net­ic mu­ta­tions

5 weeks ago
R&D

Zai Lab un­veils ear­ly lung can­cer da­ta as it looks to chal­lenge Am­gen's Imdell­tra

Last month
R&D

Ra­dio­phar­ma star­tups stay hot as Al­pha-9 bags $175M Se­ries C

Last month
Financing
Startups

Cor­rect­ed: Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Last month
R&D
Cell/Gene Tx

A Q&A with a No­bel Prize win­ner; Pfiz­er meets with Star­board; J&J re­ports Q3 earn­ings; and more

Last month
Weekly

Amy­lyx presents full Phase 2 da­ta for with­drawn ALS drug in an­oth­er rare ge­net­ic dis­ease

Last month
R&D

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Last month
Pharma
FDA+

FDA places hold on No­vavax's Covid-flu and stand­alone in­fluen­za vac­cines

Last month
R&D
FDA+

MeiraGTx's stock ris­es on small Parkin­son's gene ther­a­py dataset

Last month
R&D
Cell/Gene Tx

Pfiz­er's sit­u­a­tion with Star­board; Meet End­points' 2024 Women in Bio­phar­ma; No­bel Prizes high­light AI era

Last month
Weekly

WuXi com­pa­nies con­sid­er sale of units im­pact­ed by Biose­cure; J&J, Bay­er trim staff; Ron Re­naud’s lat­est biotech; ...

Last month
Weekly

Tar­get­ing No­var­tis' Scem­blix, En­liv­en lays out case for leukemia drug in ear­ly re­sults

Last month
R&D

Po­sei­da shares in­cre­men­tal Phase 1 up­date for Roche-part­nered off-the-shelf CAR-T

Last month
R&D
Cell/Gene Tx

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

Last month
Pharma
FDA+

A Parkin­son's drug that Ab­b­Vie ac­quired from Cerev­el suc­ceeds in an­oth­er Phase 3

Last month
R&D

Mer­ck­'s LAG-3 plus Keytru­da com­bo fails Phase 3 in col­orec­tal can­cer

2 months ago
R&D

Am­gen re­ports dual Phase 3 wins in atopic der­mati­tis and myas­the­nia gravis

2 months ago
R&D

Bio­gen, UCB de­clare Phase 3 lu­pus win and prep a sec­ond tri­al, but de­tails are scant

2 months ago
R&D

Black Di­a­mond treads wa­ter on small snap­shot of Phase 2 lung can­cer da­ta

2 months ago
R&D

John Car­roll on his can­cer di­ag­no­sis; #ES­MO's biggest sur­prise; Lykos' bad trip; Rate cuts, and more

2 months ago
Weekly

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

2 months ago
R&D
Pharma

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

2 months ago
Pharma

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

2 months ago
R&D
AI
First page Previous page 12345 Next page Last page
A service from the Financial Times